Cargando…

Resistant mutations in CML and Ph(+)ALL – role of ponatinib

In 2012, ponatinib (Iclusig(®)), an orally available pan-BCR-ABL tyrosine kinase inhibitor (TKI) developed by ARIAD Pharmaceuticals, Inc., was approved by the US Food and Drug Administration for use in resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Geoffrey D, Bruno, Benjamin J, Lim, Carol S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208348/
https://www.ncbi.nlm.nih.gov/pubmed/25349473
http://dx.doi.org/10.2147/BTT.S50734